Class / Patent application number | Description | Number of patent applications / Date published |
514535000 | The nitrogen of the Z radical is directly bonded to a benzene ring which is directly bonded to the C(=O) group | 40 |
20080227859 | Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same - The present invention relates to a tetrafluorobenzyl derivative and a pharmaceutical composition for prevention and treatment of acute and chronic neurodegenerative disease in central nervous system and ophthalmic diseases containing the same. The tetrafluorobenzyl derivative of the present invention can effectively be used to prevent and treat chronic neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease, degenerative brain disease such as epilepsy and ischemic brain disease such as stroke. | 09-18-2008 |
20080255232 | Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation - Compounds useful in the treatment of disorders characterized by deposits of amyloid aggregates are herein described together with pharmaceutical compounds containing the same. In particular the compounds of the present invention are those having the Formula (I) as reported below, where the radicals have the meaning indicated in the description. | 10-16-2008 |
20080306149 | Use for a Composition Comprising Chloroprocaine Hcl, a New Composition Comprising Chloroprocaine Hcl and a Method for Its Manufacture - The present invention concerns a new use for a composition comprising chloroprocaine HCl, and in particular its use for the manufacture of a drug for intrathecal narcosis. The present invention also concerns a new composition comprising chloroprocaine HCl, being particularly suited to this new use, as well as a new method for manufacturing said composition. | 12-11-2008 |
20090253786 | Synthesis, anti-allergic, anti-asthmatic and anti-inflammatory activities of CEE-1 and CEE-2 - “Enhydrazone esters of formula (I): wherein R is methyl or ethyl group have been synthesized. The compounds of formula (I) are potent inhibitors of degranulation of both mast cells and eosinophils. These compounds also suppress cytokines generation by leukocytes. These biological activities are relevant to the prevention and/or treatment of asthma, allergies and inflammatory diseases. It is known to the art that inhibitors of mast cell degranulation such as cromolyn sodium and nedocromil sodium are used in the treatment of asthma and other allergic diseases. Inhibitors of cytokine generation, such as steroids, are also useful in the prevention and treatment of inflammatory diseases as well as asthma and allergies”. | 10-08-2009 |
20090253787 | SHORT-ACTING SEDATIVE HYPNOTIC AGENTS FOR ANESTHESIA AND SEDATION - The invention provides compounds compositions and methods useful for inducing or maintaining general anesthesia or sedation in mammals. | 10-08-2009 |
20090281181 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases - The present invention relates to a pharmaceutical composition useful for treating or preventing inflammatory disease and cell damage, and a method for treating or preventing inflammatory disease and cell damage. The present invention uses the 2-hydroxybenzoic acid derivative represented by the specific chemical formula or its pharmaceutically acceptable salt. The compound of the present invention is useful for treating or preventing cell damage and inflammatory disease including gastritis, gastric ulcer, pancreatitis, colitis, arthritis, diabetes, arteriosclerosis, nephritis, hepatitis, Alzheimer's disease, Parkinson's disease and Lou Gehrig's disease. | 11-12-2009 |
20090286876 | NEUROPROTECTIVE BENZOATE AND BENZAMIDE COMPOUNDS - The invention provides a therapeutic method for treating at least one symptom of a neurological disorder or disease such as Alzheimer's disease in a mammal, such as a human, wherein the toxicity of a pathogen of β amyloid peptide and/or glutamate in mammalian cells is implicated and inhibition of the subsequently-induced pathological pathways is desired comprising administering to a mammal in need of such therapy, an effective amount of an N-arylamide or an (N-aminoalkyl)benzamide, including pharmaceutically acceptable salts thereof. | 11-19-2009 |
20100010085 | Compositions and Methods for Treating Jellyfish Stings - Methods and compositions for treating skin conditions, in particular jellyfish stings, are provided. | 01-14-2010 |
20100063146 | METHOD FOR TREATING DISORDERS RELATED TO COMPLEMENT ACTIVATION - A method for treating or preventing a complement activated T-cell mediated disorder in a subject includes administering a therapeutically effective amount of a pharmaceutical composition to the subject. The pharmaceutical composition includes at least one amidine compound or pharmaceutically acceptable salt. | 03-11-2010 |
20100267827 | PHENYL-PRENYL-ETHER DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS - The present invention is related to a family of phenyl-prenyl-ether derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or 5 Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder. | 10-21-2010 |
20110060043 | INHIBITORS OF CELL PROLIFERATION AND USES THEREOF - The present invention provides novel compounds that inhibit cell proliferation and uses of these compounds for treating, ameliorating or preventing diseases, conditions or disorders benefiting from the inhibition hyperproliferation. | 03-10-2011 |
20110086913 | METHODS FOR TREATING MYOFASCIAL, MUSCLE, AND/OR BACK PAIN - The present disclosure is drawn to methods for treating myofascial pain, muscle pain, back pain, or combinations of these pains. Specifically, a method for treating myofascial pain, muscle pain, back pain, or combinations thereof includes the application of an analgesic system to a skin surface of a subject experiencing the pain and maintaining the analgesic system on the skin surface for a period of time of at least 30 minutes. The analgesic system applied to the skin surface can include a heating component and a local anesthetic formulation which includes at least one local anesthetic. The heating component can be capable of heating the skin surface to a temperature of 36° C. to 42° C. | 04-14-2011 |
20110124727 | Oxybuprocaine-Containing Analgesic/Antipruritic External Preparation - An analgesic/antipruritic external preparation that includes a local anesthetic, has fewer side effects, and has an excellent therapeutic effect on pain and itching of the skin is provided. The analgesic/antipruritic external preparation includes oxybuprocaine or a pharmaceutically acceptable salt thereof as an active ingredient, and the oxybuprocaine or a pharmaceutically acceptable salt thereof is contained in an amount of 0.1 to 60 wt %, more preferably 1 to 40 wt %, and most preferably 5 to 30 wt %. The analgesic/antipruritic external preparation has a dosage form as an external preparation wherein the dosage form is an ointment, a solution, a suspension, an emulsion, a lotion, a cataplasm, a tape, an aerosol, or a powder for external use. | 05-26-2011 |
20110269834 | COMPOUNDS AND METHODS FOR TREATING RESPIRATORY DISEASES - Described herein are compounds and compositions, and methods for using the compounds and compositions, for treating respiratory diseases and illness, such as severe acute respiratory syndrome (SARS). | 11-03-2011 |
20120004303 | METHOD OF DISPENSING A TEETHING GEL WITH A METERED DOSE APPLICATOR - A method of treating periodontal pain from teething that uses an applicator to dispense a medicament composition, wherein said applicator dispenses a metered dose of a therapeutic amount of said medicament composition. | 01-05-2012 |
20120101157 | 4,5-Diamino-3-Halo-2-Hydroxybenzoic Acid Derivatives and Preparations Thereof - Disclosed are 4,5-diamino-3-halo-2-hydroxybenzoic acid derivatives and manufactures thereof. The 4,5-diamino-3-halo-2-hydroxybenzoic acid derivatives are presented by formula (I): | 04-26-2012 |
20120283326 | ANTHRANILIC ACID DERIVATIVES - Compounds of formula (I) are provided, wherein X is CH═CH, CH | 11-08-2012 |
20130096191 | Benzonatate Compositions and Methods of Use - Oral dosage forms of benzonatate useful for anti-tussive and anti-tussive/combination applications. | 04-18-2013 |
20130184345 | OLIGO-BENZAMIDE COMPOUNDS FOR USE IN TREATING CANCERS - The present invention provides bis- and tris-benzamide compounds in the treatment of breast, brain and ovarian cancers. | 07-18-2013 |
20140275248 | TREATMENT OF MOLLUSCUM CONTAGIOSUM - Methods for treating molluscum contagiosum warts include identifying a human with one or more molluscum contagiosum warts and applying an anti-infective composition to the one or more warts. The anti-infective composition comprises at least one anti-infective agent in a liquid carrier, such as an organohalide. The liquid carrier includes a tissue penetrating component for rapid penetration of the anti-infective agent into the one or more molluscum contagiosum warts. Application of the anti-infective composition to molluscum contagiosum warts causes the warts to turn black and/or fall off the skin in less than about 5 days. | 09-18-2014 |
20140288174 | WNT/B-CATENIN INHIBITORS AND METHODS OF USE - This disclosure relates to inhibitors of the Wni pathway, and compositions comprising the same, as well as to their use in the treatment of disorders characterized by the activation of Writ pathway signaling (e.g., cancer), as well as to the modulation of cellular events mediated by VVnt pathway signaling. | 09-25-2014 |
20140303248 | N-BENZYLANILINE DERIVATIVE AND USES THEREOF - A N-benzylaniline derivative and uses thereof. The derivative is a compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound protects against cerebral ischemia/reperfusion injury and has analgesic action for chronic pathologic pain, and may be used to treat cerebral apoplexy, neuropathic pain, and inflammatory pain. Moreover, because of the unique mechanism of action of the compound, the compound can be used to treat epilepsy, affective disorder, and neurodegenerative diseases. | 10-09-2014 |
514536000 | With an agent to enhance topical absorption or with a stabilizing agent | 7 |
20080214664 | ANESTHETIC SPRAY COMPOSITION - An anesthetic spray composition suitable for application to the back of the throat comprising a topical anesthetic and a mucoadhesive polymer. | 09-04-2008 |
20100240749 | ANESTHETIC SPRAY COMPOSITION - An anesthetic spray composition suitable for application to the back of the throat comprising a topical anesthetic and a mucoadhesive polymer. | 09-23-2010 |
20130079404 | TOPICAL FORMULATION - It has been discovered that certain combinations of compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of active agents. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation. There is described herein a topical formulation comprising (i) an active agent selected from at least one of lidocaine and tetracaine; (ii) a first compound, and (iii) a second compound, wherein the first compound and second compound are different, and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate. | 03-28-2013 |
20130131166 | BIOADHESIVE COMPOSITIONS FOR EPITHELIAL DRUG DELIVERY - Disclosed are compositions and methods for treating a disease, such as infection, pain, or inflammation, by using the compositions. Particularly, disclosed is a method of treating oral pain, wherein, the above-described compositions are applied to the oral mucosa; the compositions undergo in-situ gelation, optimal adhesion to the oral mucosa, controlled erosion and controlled release of the active ingredient, i.e., benzocaine, which provides a superior degree of pain relief or analgesia for an extended period of time. | 05-23-2013 |
20140364495 | HIGHLY PENETRATING COMPOSITIONS AND METHODS FOR TREATING DISORDERED TISSUES - Compositions and methods for treating disordered tissues, such as caused by pathogens and/or by toxins. The treatment compositions include an anti-infective active agent, a liquid carrier, and benzocaine in an amount so that the treatment composition penetrates more quickly into disordered tissue compared to the treatment composition in the absence of the benzocaine. In addition, the benzocaine can increase residence time of the anti-infective active in the treatment area. The preferred anti-infective active agent can be an organohalide, such as a quaternary ammonium halide compound, an example of which is benzalkonium chloride. The treatment compositions and methods may employ the use of an applicator adapted for use in promoting penetration of the treatment composition and/or agitation of the disordered tissue to further enhance penetration. | 12-11-2014 |
20140364496 | HIGHLY PENETRATING COMPOSITIONS AND METHODS FOR TREATING DISORDERED TISSUES - Compositions and methods for treating disordered tissues, such as caused by pathogens and/or by toxins. The treatment compositions include an anti-infective active agent, a liquid carrier, and benzocaine in an amount so that the treatment composition penetrates more quickly into disordered tissue compared to the treatment composition in the absence of the benzocaine. In addition, the benzocaine can increase residence time of the anti-infective active in the treatment area. The preferred anti-infective active agent can be an organohalide, such as a quaternary ammonium halide compound, an example of which is benzalkonium chloride. The treatment compositions and methods may employ the use of an applicator adapted for use in promoting penetration of the treatment composition and/or agitation of the disordered tissue to further enhance penetration. | 12-11-2014 |
20150297550 | SUSTAINED RELEASE OF TOPICAL ANESTHETICS - A composition and method to alleviate oral mucosal discomfort and irritation in an orthodontic patient. A wax matrix containing less that 15% analgesic/anesthetic agent such as benzocaine and excipients enhanced and extended release of the analgesic/anesthetic agent compared to known art formulations. The composition exhibited desirable aesthetic properties, was easy to apply, and the relatively lower concentration of active agent provided enhanced safety. | 10-22-2015 |
514537000 | With an additional active ingredient | 11 |
20110112189 | METHODS OF TREATING PAINS ASSOCIATED WITH NEUROMA, NERVE ENTRAPMENT, AND OTHER CONDITIONS - The present disclosure is drawn to methods for treating nerve entrapment pain; neuroma pain; headache associated with neuralgia; connective tissue pain such as iliotibial band pain, blood vessel pain, tendinopathy pain, medial tibial stress syndrome pain, bursitis, etc.; arthritis pain such as osteoarthritis pain or rheumatoid arthritis pain; pain associated with injury such as fracture, severance, break, sprain, strain, tear, point pain, (e.g., trigger point pain or hit point pain), focal pain, or bruise; or combinations of these pains. Specifically, a method for treating various types of pain includes the application of an analgesic system to a skin surface of a subject experiencing the pain and maintaining the analgesic system on the skin surface for a period of time of at least 30 minutes. The analgesic system applied to the skin surface can include a heating component and a local anesthetic formulation which includes at least one local anesthetic. The heating component can be capable of heating the skin surface to a temperature of 36° C. to 42° C. | 05-12-2011 |
20120022158 | SOLID-FORMING LOCAL ANESTHETIC FORMULATIONS FOR PAIN CONTROL - Solid-forming local anesthetic formulations for pain control can include a lidocaine base and tetracaine base, polyvinyl alcohol, water, and an emulsifier. The formulation can be prepared to be in a semi-solid state prior to application to a skin surface, can form a soft solidified layer after application, and can provide pain relief when applied to a skin surface proximate a pain site. | 01-26-2012 |
20120065259 | HEAT ASSISTED LIDOCAINE AND TETRACAINE FOR TRANSDERMAL ANALGESIA - The present disclosure is drawn to methods for treating various types of pain, including pain associated nerve entrapment, neuroma, headaches, connective tissue, arthritis, injury, and/or overuse. Specifically, the method includes the application of an analgesic system to a skin surface of a subject experiencing the pain and maintaining the analgesic system on the skin surface for an application period of at least 30 minutes. Following the application period the analgesic system can be removed and the subject being treated continues to experience reduction of pain for a period of 2 to 10, or even 4 to 12 hours after removal of the analgesic system. The analgesic system applied to the skin surface can include a heating component and a local anesthetic formulation. | 03-15-2012 |
20120101158 | Surface Anesthetic Agent - Provided is an anesthetic agent which can exhibit an anesthetic effect rapidly when adhered on mucosal membranes, the skin or the like by means of application or the like in local anesthesia, particularly surface anesthesia. Prepared are: a fast-acting surface anesthetic agent containing lidocaine and ethyl paraaminobenzoate at a specific ratio; and a super fast-acting surface anesthetic agent containing lidocaine, ethyl paraaminobenzoate and adrenaline at a specific ratio. | 04-26-2012 |
20130150442 | OLIGO-BENZAMIDE COMPOUNDS AND THEIR USE IN TREATING CANCERS - The present invention includes bis- and tris-benzamide compounds that block AR signaling and have activity against prostate cancer. Uses for these compounds, and pharmaceutical compositions containing the same, also are provided. | 06-13-2013 |
20140200271 | ANTITUSSIVE COMPOSITIONS COMPRISING MEMANTINE - Memantine compositions and methods of use are described herein. In some embodiments, the compositions comprise memantine and an absorption enhancer, or memantine and an elimination enhancer, or memantine and an absorption enhancer and an elimination enhancer. | 07-17-2014 |
20140323568 | OLIGO-BENZAMIDE COMPOUNDS AND THEIR USE IN TREATING CANCERS - The present invention includes bis- and tris-benzamide compounds that block AR signaling and have activity against prostate cancer. Uses for these compounds, and pharmaceutical compositions containing the same, also are provided. | 10-30-2014 |
20150025140 | NEMATODE REPELLENT COMPOSITION - In one aspect, this invention relates to a nematode repellent composition comprising an effective nematode repellent amount of a fatty acid and an anthranilate ester. In another aspect, this invention relates to a method of repelling nematodes employing such composition. | 01-22-2015 |
20150025141 | Insect Repellent - In one aspect, this invention relates to pest repellent composition comprising a fatty acid and an anthranilate ester. In another aspect, this invention relates to a method of repelling pests employing such composition. | 01-22-2015 |
20160030368 | SINUS ANESTHESIA KIT - An apparatus and method for anesthetizing various portions of a patient's nasal sinuses. For example, a kit can be provided that includes a first agent configured to modulate a rate of absorption of a subsequently-applied topical agent by one or more nasal structures. The kit also includes a first applicator configured to apply the first agent to a first portion of the one or more nasal structures. The kit also includes a second agent configured to anesthetize the first portion of the one or more nasal structures subsequent to application of the first agent and a second applicator configured to apply the second agent to the second portion of the one or more nasal structures. | 02-04-2016 |
20160089441 | COMPOSITION FOR THE TREATMENT OF COLD SORES - A composition used in the treatment of the cold sores is composed of Water, Propylene Glycol, Mineral Oil, Behenyl Alcohol or docosanol, Benzocaine, Vitamin E tocopheryl, Sucrose Stearate, and Benzyl Alcohol. | 03-31-2016 |